Moderna is set to roll-out a new vaccine which combines the current COVID-19 shot with a flu vaccine. The two-in-one vaccine booster shot will be called mRNA-1073, according to the company. Moderna announced the first step in their novel respiratory program, which it hopes will add vaccines it is working on for respiratory syncytial virus and other respiratory diseases as an annual shot. The announcement follows Moderna’s successful rollout of its mRNA-based two-dose Covid vaccine.
CEO Stéphane Bancel said in a statement: “Today we are announcing the first step in our novel respiratory vaccine program with the development of a single dose vaccine that combines a booster against COVID-19.
“We are making progress on enrolling patients in our rare disease programs, and we are fully enrolled in our personalised cancer vaccine trial.
“We believe this is just the beginning of a new age of information-based medicines.”
The mRNA technology behind the novel vaccines have been under development for years, with the company’s jabs some of the first to be cleared for use in humans, alongside Pfizer’s.
The cutting edge vaccines work by introducing mRNA that contain instruction to make the “spike” protein of the coronavirus.
In response to these proteins, the body’s immune pathways are activated, thereby offering protection should it be exposed to the virus.
The mRNA-1073 vaccine is one of many the company said it intends to release, which are “critical for neutralisation”.
Modern’a announcement came as the company completed the rolling submission process for a licence for its new vaccine.
Moderna disclosed it has 37 different ongoing programs across 34 development candidates.
COVID-19 variants of concern are also being addressed with the new vaccines candidates, the company stated.
Bancel added: “I am proud of the progress that the Moderna team has made in advancing our best-in-class mRNA pipeline while addressing the global COVID-19 pandemic.
“We believe our mRNA platform can solve the world’s greatest health challenges, from diseases impacting millions, to ultra-rare diseases impacting dozens, to medicine personalised down to the individuals level.